BioCryst Pharmaceuticals
BCRX
116 hedge funds and large institutions have $764M invested in BioCryst Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 10 closing their positions.
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
52% more capital invested
Capital invested by funds: $501M → $764M (+$263M)
50% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 26
28% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $1.46M
13% more funds holding
Funds holding: 103 → 116 (+13)
3.02% more ownership
Funds ownership: 88.53% → 91.56% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$15.1M |
| 2 |
Janus Henderson Group
London,
|
+$7.75M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$7.33M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.03M |
| 5 |
BlackRock
New York
|
+$6.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.47M |
| 2 |
Millennium Management
New York
|
-$3.46M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.89M |
| 4 |
Renaissance Technologies
New York
|
-$1.19M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$689K |
BCRX Hedge Fund Activity: Q3 2018 in Review
116 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2018, worth a combined $764M — up 52% from $501M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BCRX positions and 10 closed out — a net gain of 13 holders — while 39 added to existing stakes and 26 trimmed.
The largest buyer was RA Capital Management, adding an estimated $15.1M. The largest seller was Fidelity Investments, cutting an estimated $4.47M.
- 116 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2018, up from 103 in Q2 2018.
- Funds reported $764M of BioCryst Pharmaceuticals stock for Q3 2018, up 52% quarter-over-quarter.
- 23 funds opened new BioCryst Pharmaceuticals positions in Q3 2018 and 10 closed out, a net change of +13 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2018 was RA Capital Management, an estimated $15.1M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $4.47M sold.
Based on aggregated 13F filings for Q3 2018.